Abbreviations: AIM2, absent in melanoma-2; BMM, bone marrow macrophage; HMDM, human monocyte-derived macrophage; LPS, lipopolysaccharide; NLR, Nodlike receptor; NLRC4, NLR-containing a card domain-4; NLRP, NLR-containing a pyrin domain; TEPM, thioglycollate-elicited peritoneal macrophage; TLR, toll-like receptor. Our data suggest that, in addition to augmenting NLRP3 inflammasome activity via NLRP3 induction, LPS boosts caspase-1 activation by the NLRP3 and AIM2
proteins that accumulate intracellularly until the inflammasome pathway is engaged.
Once activated, caspase-1 converts pro-IL-1 and pro-IL-18 into their active forms and directs their non-classical secretion. IL-1 has recently emerged as another inflammasome cytokine target, although it is not directly processed by caspase-1 (Gross et al. 2012 ).
It has long been appreciated that the maturation and secretion of IL-1 triggered by the inflammasome requires pre-treatment with a pro-inflammatory stimulus such as a toll-like receptor (TLR) agonist (e.g. the TLR4 ligand, bacterial lipopolysaccharide, LPS). Pro-IL-1 is not constitutively expressed in most cells, so it was originally believed that priming served solely to induce its expression and hence availability as a caspase-1 substrate. However, later studies demonstrated that priming also regulates the activity of the NLRP3 inflammasome via additional mechanisms upstream of substrate availability. For example, caspase-1 activation by the pore-forming toxin and NLRP3 agonist, nigericin, absolutely requires pre-treatment with a proinflammatory stimulus such as LPS (Bauernfeind et al. 2009 ). This phenomenon has been attributed to LPS-dependent upregulation of the inflammasome sensor component, NLRP3 (Bauernfeind et al. 2009 ). Here we show that the level of NLRP3 expression is not the only factor limiting caspase-1 activation, and that LPS may augment inflammasome function through additional mechanisms.
We exposed wild-type bone marrow macrophages (BMM) to the NLRP3 agonists, ATP and nigericin, with or without pre-treatment with LPS for various times. In keeping with a previous study (Bauernfeind et al. 2009 ), NLRP3-dependent caspase-1 activation was highly dependent on prior LPS exposure. In unprimed macrophages, caspase-1 activation was at the limit of detection for both ATP and nigericin treatment, whereas 6h pre-treatment with LPS potently augmented caspase-1 activation (Fig. 1A) . Interestingly, the timing of LPS priming differentially affected caspase-1 activation by ATP compared with caspase-1 activation by nigericin ( We next examined whether LPS modulates the expression of known inflammasome pathway members, as such a mechanism may underlie priming at some LPS timepoints. We first characterised the expression of inflammasome components and their cytokine targets, and detailed their regulation in multiple human and mouse macrophage populations. NLRP3 mRNA was upregulated in BMM, thioglycollateelicited peritoneal macrophages (TEPM) and human monocyte-derived macrophages (HMDM) (Fig. 1C) , in agreement with NLRP3 protein induction in BMM (Fig. 1A) .
NLRC4, another NLR sensor protein that forms a distinct inflammasome, was also moderately upregulated by 24h LPS exposure in mouse and human macrophages, suggesting LPS priming may also boost NLRC4 inflammasome function (Fig. 1D) .
Another inflammasome sensor protein, AIM2, was substantially upregulated at the mRNA level in human macrophages but was only weakly induced in mouse macrophages, probably via autocrine type I interferon (Fig. 1E) . The inflammasome adaptor, ASC was not induced at the mRNA or protein level during the 0-6h window when LPS priming was evident, although it was moderately upregulated at 24h at the mRNA, but not protein level in murine macrophages (Figs. 1B,F) . CASP1 expression was induced at 6h in mouse macrophages at the mRNA (Fig. 1G) but not the protein level ( Fig. 1A.B) . In all, these results suggest that LPS priming of NLRP3 inflammasome activation is unlikely to involve modulation of ASC and caspase-1 expression levels. LPS is well established to induce the expression of inflammasome cytokine substrates, and we characterised the time-course of their inducible expression in multiple human and mouse macrophage populations (mRNA for IL-1a, ; Fig. 1H-J) .
Various stress-associated pathways such as reactive oxygen species, K + efflux and lysosomal damage are suggested to trigger NLRP3 activity, although the precise mechanisms await full characterisation. Both nigericin (directly, due to its poreforming properties) and ATP (indirectly, via ligation of the ATP-dependent K + channel, P2X7R) trigger K + efflux, but the mechanism by which ionic flux might be sensed by NLRP3 remains unclear. LPS does not influence the expression of P2x7r mRNA in BMM (Schroder et al. 2012) , and so this is unlikely to underlie LPS priming of ATP responses. We hypothesised that LPS regulation of signalling pathways upstream of NLRP3 may also contribute to the priming phenomenon, at least for delayed priming effects. NLRP3 activation by ATP and other agonists is dependent on reactive oxygen species (ROS), although the precise role of ROS is controversial (Bauernfeind et al. 2011; Tschopp and Schroder 2010) . ROS derived from both mitochondrial respiration and the NADPH oxidase complex have been implicated . Here, we find that mRNA for two subunits of the NADPH oxidase, Cybb and Nox1, are strongly upregulated in mouse macrophages, although, interestingly this effect was not apparent in HMDM (Fig.   1K,L) . The nucleotide-binding protein, GBP5, was recently reported to promote NLRP3 inflammasome activation by ATP and nigericin (Shenoy et al. 2012) , and
Gbp5 mRNA was substantially upregulated by LPS in mouse and human macrophages (Fig. 1M) . LPS also regulated signalling molecules required for inflammasome activation by agonists other than ATP and nigericin. NLRP3
inflammasome activation downstream of C-type lectin ligation (e.g. by Candida albicans) requires the kinase, SYK, and expression of Syk mRNA was highly induced in mouse, but not human macrophages (Fig. 1N) . Thus, LPS-dependent upregulation of NADPH oxidase-, SYK-and GBP5-dependent pathways may potentiate subsequent NLRP3 inflammasome activation by specific agonists. Whilst induction of GBP5 and NADPH oxidase subunits may contribute to LPS priming at intermediate time-points (4-6h pre-treatment) they are unlikely to explain rapid LPS priming of NLRP3 responses (e.g. 0-2h pretreatment with LPS), as their upregulation by LPS occurs after the observed priming effect.
The observation that even short LPS pre-treatment times effectively boosted NLRP3
inflammasome activation suggested the existence of an LPS signalling pathway that directly influences the ability of the inflammasome complex to form, perhaps via post-translational modification or subcellular re-localization of the NLRP3 inflammasome components, ASC and caspase-1. In order to test this hypothesis, we investigated signal integration between LPS and AIM2 inflammasome pathways.
Unlike NLRP3, which is unlikely to bind directly to its diverse agonists, AIM2 binds directly to double-stranded DNA in the cytosol. AIM2 aggregation upon the DNA enables ASC-dependent clustering and auto-activation of pro-caspase-1 . Thus, should LPS signalling regulate the ability of ASC or caspase-1 to form an inflammasome, caspase-1 activation by the AIM2 inflammasome should be boosted by LPS pre-treatment, similar to our observations for NLRP3. Although our results support previous studies showing that priming is not absolutely required for AIM2 inflammasome activation by high doses of transfected DNA (Bauernfeind et al. 2009; Roberts et al. 2009 ), 4h LPS priming increased the sensitivity of AIM2 to submaximal DNA doses (e.g. 5 g) (Fig. 1O) . Importantly, AIM2 protein expression was not regulated at this timepoint (Fig. 1P) .
Mechanisms by which the TLR and inflammasome pathways intersect are highly relevant to inflammation in vivo, because many inflammasome agonists also trigger concurrent signalling by TLRs or related pro-inflammatory pathways (e.g. TNF). Our data suggest that pro-inflammatory stimuli such as LPS regulate the inflammasome pathway at many levels. In addition to transcriptional pathways triggered by LPS that upregulate expression of NLRP3, cytokine substrates (IL1/, IL18), and candidate signalling molecules upstream of NLRP3 ( Fig. 2A) , LPS increases the sensitivity or activity of the NLRP3 and AIM2 inflammasomes via other, as yet unexplained, mechanisms (Fig. 2B) . The finding that even very short priming times effectively potentiate inflammasome activation (e.g. co-stimulation of LPS plus ATP) suggests that TLR4 signalling triggers either post-translational modifications or subcellular relocalization of proteins required for full inflammasome activation. It is also possible that LPS acutely regulates the expression and/or functions of as yet undefined accessory proteins required for optimal inflammasome activation. NLRP3 appeared to have more stringent LPS priming requirements than AIM2, suggesting that whilst there may be some potentiation of ASC and caspase-1 function shared by both pathways, a more critical point of LPS regulation exists upstream of NLRP3.
In addition to permitting full and timely activation of the AIM2 and NLRP3
inflammasome pathways, TLR4 co-engagement may also suppress inflammasomedependent inflammation at later time-points, by promoting pathways that limit inflammasome signalling and effectors. Such candidate LPS-regulated pathways include p62-mediated autophagic destruction of NLRP3 (Shi et al. 2012) , IFN-mediated suppression of NLRP1/3 activity and availability of pro-IL-1/ substrates (Guarda et al. 2011) , and antagonism of the IL-1/ receptor signalling via the natural antagonist, IL1RN (Liao et al. 1984) , given that mRNA levels of p62, IFNB, and IL1RN are all upregulated by LPS (http://macgate.qfab.org) (Schroder et al. 2012 ).
In summary, pro-inflammatory signalling by TLR ligands is likely to regulate the inflammasome pathway at multiple levels. As the precise mechanisms directing inflammasome sensing and assembly are still unclear, a closer examination of mechanisms of signal integration between the TLR and inflammasome pathways may yield important insight into the molecular schemes underlying inflammasome assembly, activation and deactivation. 
